Menu Search
Equities

United Therapeutics Corp

UTHR:NSQ

United Therapeutics Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)372.18
  • Today's Change4.82 / 1.31%
  • Shares traded65.39k
  • 1 Year change+61.48%
  • Beta0.5506
Data delayed at least 15 minutes, as of Nov 22 2024 17:21 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy4
Outperform5
Hold5
Sell1
Strong Sell0

Share price forecast in USD

The 13 analysts offering 12 month price targets for United Therapeutics Corporation have a median target of 390.00, with a high estimate of 600.00 and a low estimate of 302.00. The median estimate represents a 6.16% increase from the last price of 367.36.
High63.3%600.00
Med6.2%390.00
Low-17.8%302.00

Earnings history & estimates in USD

On Oct 30, 2024, United Therapeutics Corporation reported 3rd quarter 2024 earnings of 6.39 per share. This result was in line with the consensus of the 13 analysts following the company and exceeded last year's 3rd quarter results by 18.77%.
The next earnings announcement is expected on Feb 19, 2025.
Average growth rate+6.65%
United Therapeutics Corporation reported annual 2023 earnings of 19.81 per share on Feb 21, 2024.
Average growth rate+22.78%
More ▼

Revenue history & estimates in USD

United Therapeutics Corporation had 3rd quarter 2024 revenues of 748.90m. This bettered the 722.58m consensus of the 12 analysts covering the company. This was 47.74% above the prior year's 3rd quarter results.
Average growth rate+5.34%
United Therapeutics Corporation had revenues for the full year 2023 of 2.33bn. This was 20.20% above the prior year's results.
Average growth rate+12.77%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.